
A bond rebound would not erase the downtrend
The Morning Show weighs a possible bond reversal against the larger trend, while John Salama and JC Parets examine whether attractive charts also offer attractive option prices.
IDEAS / Tickers
ARK Genomic Revolution ETF

The Morning Show weighs a possible bond reversal against the larger trend, while John Salama and JC Parets examine whether attractive charts also offer attractive option prices.

A former favorite bearish trade was testing its 200-day average again. On July 29, 2024, Salama explained why he had stepped aside and why finding a replacement hedge was becoming harder.

When a viewer asked about CRISPR Therapeutics on June 29, 2023, Strazza brought up another genomics stock. Its trading range had narrowed for months, and $54 gave him a price to work against.